Table 2.

Univariate and multivariable analysis of BM and LM on OS and TTF.

	OS			TTF
	N	Mediana (months)	HRb (95% CI)	N	Mediana (months)	HRb (95% CI)
Model 1c
Bone Metastasis
Yes	693	14.9	1.38 (1.22, 1.56)	678	5.7	1.19 (1.07, 1.33)
No	1334	25.1	reference	1319	7.6	reference
P-value		<0.0001	<0.0001		<0.0001	0.001
Liver Metastasis
Yes	381	14.3	1.37 (1.18, 1.58)	371	5.5	1.15 (1.01, 1.32)
No	1646	22.2	reference	1626	7.3	reference
P-value		<0.0001	<0.0001		0.013	0.032
Model 2d
Bone + Liver +/− Othere	147	10.9	1.82 (1.47, 2.26)	140	4.2	1.45 (1.19, 1.78)
Bone +/− Othere	546	16.2	1.40 (1.22, 1.62)	538	6.4	1.16 (1.03, 1.32)
Liver +/− Othere	234	18.2	1.42 (1.17, 1.73)	231	6.6	1.10 (0.93, 1.30)
Othere	1100	27.1	reference	1088	7.8	reference
P-value		<0.0001	<0.0001		<0.0001	0.001

^aLog rank test.

^bWald chi-square test from multivariable Cox regression adjusted for the IMDC risk factors, including time from diagnosis to treatment < 1 year, Karnofsky performance status <80, hemoglobin < upper limit of normal, neutrophilia, thrombocytosis, and hypercalcemia.

^cIn model 1, BM (yes versus no) and LM (yes versus no) were evaluated as two individual factors.

^dIn model 2, patients were classified into four groups based on the combination of BM and LM (presence of both BM and LM, presence of either BM or LM, or other metastases).

^eOther is defined as sites of metastasis excluding bone and liver.